Last updated: September 23, 2026
BESIVANCE is a 0.6% besifloxacin ophthalmic suspension developed around three formulation priorities: maintaining a high local antibiotic concentration, improving ocular residence time, and preserving tolerability in the inflamed postoperative eye. Its excipient system uses boric acid, edetate disodium, mannitol, poloxamer 407, purified water, and pH adjusters. The product’s commercial opportunity is concentrated in differentiated ophthalmic delivery, preservative-minimized formulations, hospital and ambulatory surgery channels, and lifecycle products rather than broad generic exclusivity.
What is BESIVANCE and how does its formulation work?
BESIVANCE contains besifloxacin hydrochloride equivalent to 0.6% besifloxacin. It is indicated for bacterial conjunctivitis and is administered as an ophthalmic suspension rather than a clear solution.[1]
The formulation is designed for topical delivery to the ocular surface. Besifloxacin is a fluoroquinolone antibiotic with activity against bacterial DNA gyrase and topoisomerase IV. The suspension format allows the product to deliver a relatively high drug concentration despite besifloxacin’s limited aqueous solubility.
BESIVANCE uses Bausch + Lomb’s DuraSite ophthalmic delivery platform. DuraSite is intended to increase formulation retention on the ocular surface and reduce rapid drainage through the nasolacrimal system. The label instructs patients to shake the bottle well before use, which confirms that the product is a dispersed suspension rather than a fully dissolved solution.[1]
What excipients are in BESIVANCE?
| Excipient |
Likely formulation role |
Commercial relevance |
| Boric acid |
Buffering and tonicity control |
Supports ocular compatibility and pH management |
| Edetate disodium |
Chelating agent |
Binds trace metals that can catalyze degradation or support microbial growth |
| Mannitol |
Tonicity adjustment and possible suspension-support function |
Helps align the formulation with ocular tolerability requirements |
| Poloxamer 407 |
Surfactant and wetting agent |
Helps disperse besifloxacin particles and improve dose uniformity |
| Purified water |
Vehicle |
Main liquid phase |
| Hydrochloric acid and sodium hydroxide |
pH adjustment |
Used to achieve the target formulation pH |
The FDA prescribing information identifies these inactive ingredients and states that hydrochloric acid and sodium hydroxide may be used for pH adjustment.[1] The label does not provide a full quantitative excipient composition.
How does the BESIVANCE excipient strategy create product differentiation?
The formulation strategy addresses the main technical problems associated with topical ophthalmic antibiotics: short ocular residence time, poor wetting of hydrophobic drug particles, dose nonuniformity, and irritation from preservatives or aggressive surfactants.
Suspension design
Besifloxacin is delivered as a 0.6% suspension. This enables a high nominal drug concentration without requiring complete dissolution in the aqueous vehicle. The tradeoff is the need for consistent particle size, controlled sedimentation, rapid redispersion, and reliable delivered dose throughout the bottle life.
For a suspension product, commercial quality depends on more than assay. Critical attributes include:
- Particle-size distribution
- Sedimentation rate
- Redispersibility
- Viscosity
- Dose uniformity
- Container compatibility
- Microbial quality
- Stability after repeated opening
These attributes create manufacturing and analytical barriers that are more difficult to reproduce than those of a simple aqueous antibiotic solution.
Poloxamer 407
Poloxamer 407 is a nonionic surfactant and wetting agent. In BESIVANCE, it likely supports dispersion of besifloxacin particles and reduces aggregation. Surfactant concentration must be controlled because excessive surfactant can increase ocular irritation, alter viscosity, or affect suspension stability.
Poloxamer 407 also provides a potential formulation-development lever. A competing product could attempt to improve redispersibility, reduce shaking requirements, or extend residence time by modifying the surfactant and polymer system. Any change would require comparative work on comfort, dose uniformity, particle morphology, and drug release.
Boric acid and mannitol
Boric acid and mannitol support pH and tonicity management. Ophthalmic formulations must balance antimicrobial stability with ocular comfort. Excessively hypotonic or hypertonic formulations can increase stinging and reflex tearing, which may reduce effective ocular exposure.
The combination gives the developer a relatively conventional excipient framework. That can support regulatory familiarity while preserving room for optimization through concentration, pH, viscosity, particle engineering, and packaging.
Edetate disodium
Edetate disodium can reduce metal-catalyzed degradation and improve preservative or antimicrobial control. It may also affect the chemical environment at the particle-water interface. In a fluoroquinolone suspension, chelation must be evaluated against potential interactions with the active ingredient, container components, and manufacturing equipment.
What formulations are protected by the BESIVANCE product strategy?
The commercial protection of BESIVANCE is likely to depend on the combined product architecture rather than a single excipient.
Relevant protection categories include:
- Besifloxacin composition and salt form. These rights cover the active pharmaceutical ingredient or specific chemical forms.
- Ophthalmic suspension composition. Claims may cover besifloxacin concentration, excipient classes, pH, viscosity, particle size, or physical stability.
- Ocular delivery technology. DuraSite-related rights may cover retention-enhancing or bioadhesive ophthalmic vehicles.
- Manufacturing process. Process claims can address particle milling, homogenization, order of addition, sterilization, filling, and redispersion control.
- Method-of-use claims. These may cover treatment of bacterial conjunctivitis or postoperative ocular infection.
The FDA label cited in this analysis identifies the formulation and delivery platform but does not itself establish the current patent status of each claim. Patent scope must be assessed separately through USPTO records, Orange Book entries, prosecution histories, and litigation records.
What is the Orange Book status of BESIVANCE?
BESIVANCE is an FDA-approved prescription ophthalmic product. Its regulatory status is different from that of a biologic, so biosimilar pathways do not apply. A competing product would generally pursue an abbreviated new drug application, provided it can establish pharmaceutical equivalence, bioequivalence or appropriate local equivalence, and manufacturing compliance.
For an ophthalmic suspension, the regulatory burden can be higher than for a simple solution. FDA review may focus on:
- Active ingredient identity and strength
- Dosage-form equivalence
- Particle-size distribution
- In vitro release or performance
- Microbial quality
- Sterility assurance
- Container-closure integrity
- Preservative or antimicrobial effectiveness
- Comparative clinical or pharmacodynamic evidence where required
An ANDA applicant may face practical challenges even where broad active-ingredient patents have expired. Suspension performance and manufacturing reproducibility can create regulatory and commercial barriers independent of patent term.
When does BESIVANCE lose exclusivity?
BESIVANCE’s commercial exclusivity is determined by several separate dates:
| Exclusivity category |
Relevance to BESIVANCE |
| New chemical entity exclusivity |
Applies only if the FDA granted the product the relevant NCE status |
| Orphan exclusivity |
Not generally expected for bacterial conjunctivitis |
| Pediatric exclusivity |
Could add six months if granted |
| Listed patents |
May delay approval or launch of an ANDA under Paragraph IV procedures |
| Regulatory exclusivity |
Depends on the FDA approval history |
| Trade-secret manufacturing know-how |
Has no fixed statutory expiry |
BESIVANCE was approved in 2009.[2] The principal commercial question is no longer simply whether the original active-ingredient patent remains in force. It is whether any enforceable formulation, delivery-system, method-of-use, or manufacturing claims can block or delay an ANDA applicant.
Which companies are challenging BESIVANCE?
Publicly visible competition in ophthalmic antibacterials includes generic and branded products containing moxifloxacin, gatifloxacin, ciprofloxacin, ofloxacin, and besifloxacin. Potential competitors include large generic manufacturers, ophthalmology-focused companies, and contract developers with sterile ophthalmic manufacturing capabilities.
A Paragraph IV challenge would generally target one or more listed patents and assert that the patent is invalid, unenforceable, or not infringed. A commercial entrant could also pursue a non-infringement strategy by using a different excipient system, particle-size range, delivery platform, or manufacturing process.
The principal competitive risks are:
- A low-cost generic besifloxacin suspension
- A clear-solution antibiotic with simpler administration
- A preservative-free or unit-dose product
- A longer-residence formulation with fewer daily doses
- A combination product that pairs an antibiotic with an anti-inflammatory agent
- A postoperative protocol that reduces demand for stand-alone antibiotic drops
What generic entry risks exist for BESIVANCE?
Generic entry would likely produce price erosion, formulary substitution, and pressure on ophthalmology-channel margins. The magnitude would depend on whether the first entrant is therapeutically substitutable and whether the generic reproduces the product’s suspension performance.
Generic launch scenarios
| Scenario |
Expected commercial effect |
| One approved generic |
Moderate price pressure; brand may retain surgeon loyalty |
| Multiple generic entrants |
Rapid reimbursement compression and formulary substitution |
| Generic with different vehicle |
Possible clinical differentiation based on comfort or redispersion |
| Authorized generic |
Faster erosion of third-party generic economics |
| No immediate generic |
Continued value from brand familiarity and delivery-platform differentiation |
The main technical barrier is not only matching 0.6% besifloxacin. A competitor must produce a sterile suspension with acceptable physical stability, consistent dosing, and comparable ocular performance.
How strong is the BESIVANCE patent estate?
The patent estate should be evaluated as a layered portfolio:
- Active-ingredient patents have the greatest historical importance but are normally the first layer to expire.
- Formulation patents can extend protection if they claim a narrow combination of besifloxacin, excipients, particle characteristics, or delivery properties.
- Delivery-platform patents may protect broader technology used across multiple ophthalmic products.
- Manufacturing patents can limit practical design-around options even when composition claims are narrow.
- Method-of-use claims may have limited blocking value if prescribers can use the same product for nonclaimed indications or if generic labeling is carved out.
Patent strength depends on claim breadth, prosecution amendments, written-description support, prior-art exposure, terminal disclaimers, and evidence that the claimed formulation produces a measurable benefit. Claims directed only to conventional excipient combinations may face greater validity risk than claims tied to defined physical properties or reproducible performance.
What commercial opportunities exist for BESIVANCE excipients?
The strongest opportunities are lifecycle extensions that improve convenience, tolerability, or manufacturing economics.
Preservative-free unit-dose BESIVANCE
A preservative-free presentation could target patients with ocular-surface disease, frequent postoperative dosing, contact-lens-related irritation, or known sensitivity to preservatives. Unit-dose packaging would raise manufacturing and packaging costs but could support hospital, surgery-center, and premium retail positioning.
Improved redispersion
A formulation that requires less vigorous shaking could reduce administration errors. Opportunities include particle engineering, modified wetting systems, optimized viscosity, or alternative polymeric vehicles. The product would need to preserve dose uniformity throughout shelf life.
Longer ocular residence
A higher-retention formulation could support lower dosing frequency or reduce washout caused by blinking and tearing. This opportunity is technically attractive but requires evidence that increased residence does not increase irritation, blurred vision, or drug exposure beyond acceptable levels.
Combination therapy
A besifloxacin and corticosteroid combination could target postoperative inflammation and infection in a single product. The regulatory and patent burden would be substantial because the developer would need to establish compatibility, stability, dosing rationale, and safety for the combined active ingredients.
Alternative packaging
Multidose preservative-free systems, metered-dose pumps, and improved suspension bottles could reduce contamination risk and improve dose consistency. Packaging patents and device rights could provide a separate commercial moat.
How does BESIVANCE compare with competing ophthalmic antibiotics?
| Product type |
Formulation advantage |
Main limitation |
| BESIVANCE |
High-strength besifloxacin suspension with retention-focused delivery |
Requires shaking and suspension manufacturing control |
| Moxifloxacin solution |
Simple administration and clear solution |
May have less formulation-based differentiation |
| Ciprofloxacin suspension or ointment |
Established generic availability |
Ointment or suspension attributes may reduce convenience |
| Ofloxacin solution |
Low-cost and familiar |
Older molecule and limited premium positioning |
| Besifloxacin generic |
Potentially equivalent antibacterial product at lower price |
Must reproduce suspension quality and regulatory performance |
BESIVANCE has its strongest commercial position where the prescriber values a branded, high-strength fluoroquinolone suspension and where formulation handling is accepted. Its vulnerability is greatest in price-sensitive channels and formularies that prioritize generic fluoroquinolone solutions.
Key Takeaways
- BESIVANCE contains 0.6% besifloxacin in an ophthalmic suspension.
- Its listed excipients are boric acid, edetate disodium, mannitol, poloxamer 407, purified water, and pH adjusters.
- The formulation strategy targets particle wetting, ocular tolerability, suspension stability, and ocular retention.
- DuraSite and suspension manufacturing provide differentiation beyond the active ingredient.
- Generic risk depends on formulation equivalence, patent barriers, manufacturing capability, and payer substitution.
- The most credible lifecycle opportunities are preservative-free packaging, improved redispersion, longer residence, combination therapy, and device-led differentiation.
- Biosimilar competition is not relevant because BESIVANCE is a small-molecule ophthalmic drug.
- Formulation and process know-how may remain commercially relevant after core active-ingredient exclusivity expires.
FAQs
Is BESIVANCE preservative-free?
The FDA label lists no benzalkonium chloride among the inactive ingredients. It identifies boric acid, edetate disodium, mannitol, poloxamer 407, purified water, and pH adjusters.[1]
Does BESIVANCE require shaking?
Yes. BESIVANCE is an ophthalmic suspension, and the label instructs patients to shake the bottle well before use.[1]
Is DuraSite an excipient in BESIVANCE?
DuraSite is a delivery platform rather than a conventional single excipient designation. The FDA label identifies the inactive ingredients separately and describes BESIVANCE as an ophthalmic suspension.[1]
Can a generic manufacturer use the same BESIVANCE excipients?
A generic manufacturer may use the same excipients if the formulation satisfies FDA requirements and does not infringe enforceable patent claims. The applicant must still demonstrate appropriate pharmaceutical equivalence, product quality, and performance.
What is the most valuable lifecycle opportunity for BESIVANCE?
A preservative-free, multidose or unit-dose presentation combined with improved suspension redispersion has the clearest commercial rationale. It could address tolerability, administration accuracy, and postoperative prescribing preferences without requiring a new antibacterial mechanism.
References
-
U.S. Food and Drug Administration. (n.d.). BESIVANCE (besifloxacin hydrochloride ophthalmic suspension) prescribing information. Bausch & Lomb Incorporated.
-
U.S. Food and Drug Administration. (2009). Drugs@FDA: BESIVANCE application and approval records. FDA.
